HLA-G/LILRBs：癌症免疫治疗的挑战。
HLA-G/LILRBs: A Cancer Immunotherapy Challenge.
机构信息
Department of Research in Hemato-Immunology, Saint-Louis Hospital, Atomic Energy and Alternative Energies Agency, Paris, France; Paris University, U976 HIPI Unit, IRSL, Paris, France.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific institute, Milan, Italy.
出版信息
Trends Cancer. 2021 May;7(5):389-392. doi: 10.1016/j.trecan.2021.01.004. Epub 2021 Feb 6.
Despite some success, many patients do not benefit from immunotherapy. New strategies to improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a combination of immunotherapy with antiangiogenic treatments. Here, we propose the therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity when combined with antiangiogenic therapies.
尽管取得了一些成功，但许多患者并未从免疫疗法中受益。提高临床疗效的新策略包括鉴定新的免疫检查点（IC）靶点，或联合免疫疗法与抗血管生成治疗。在这里，我们提出了 IC、HLA-G/LILRB 的治疗用途，并探讨了其与抗血管生成治疗联合使用时增强的协同抗肿瘤活性。
Zotero 插件